首页 | 本学科首页   官方微博 | 高级检索  
     


The Effect of miR-200c Inhibition on Chemosensitivity (5- FluoroUracil) in Colorectal Cancer
Authors:Korosh Heydari  Massoud Saidijam  Mohammad reza Sharifi  Fatemeh Karimi dermani  Sara Soleimani Asl  Nooshin Shabab  Rezvan Najafi
Affiliation:1.Research Center for Molecular Medicine,Hamadan University of Medical Sciences,Hamadan,Iran;2.Department of Genetics and Molecular Biology, School of Medicine,Isfahan University of Medical Sciences,Isfahan,Iran;3.Department of Anatomy, Faculty of Medicine,Hamadan University of Medical Sciences,Hamadan,Iran;4.Endometrium and Endometriosis Research Center,Hamadan University of Medical Sciences,Hamadan,Iran
Abstract:5-Fluorouracil (5-FU) as a chemotherapeutic drug is used to treat colorectal cancer (CRC). However, 5-FU is associated with acquired CRC resistance, which decreases the therapeutic potential of 5-FU. Several studies indicated that miR-200c is also involved in chemotherapeutic drug resistance, but the exact mechanism of miR-200c mediated chemoresistance has not yet been fully understood. In this study, we examined the effect of inhibition of miR-200c on the sensitivity of HCT-116 cells to 5-FU. HCT-116 cells were transfected with LNA-anti- miR-200c for 48 h. mRNA expression of miR-200c was investigated by qRT-PCR. The protein expression of phosphatase and tensin homolog (PTEN) and E-cadherin were evaluated by western blotting. Annexin V/ PI staining and caspase 3 activity were used to detect apoptosis. LNA-anti-miR-200c inhibited the miR-200c expression in the transfected cells compared with that in the control group. LNA-anti-miR-200c suppressed the expression of PTEN and E-cadherin independent of the presence of the chemotherapeutic drug 5-FU. LNA-anti-miR-200c reduced the 5-FU-induced apoptosis and caspase 3 activity. miR-200c, as a novel prognostic marker in CRC, can be a potential therapeutic approach to overcome chemoresistance during 5-FU chemotherapy.
Keywords:
本文献已被 SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号